REGENXBIO Inc. Retained Earnings
REGENXBIO Inc. (RGNX) had Retained Earnings of -$1.19 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$1.19B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$1.22B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$1.13B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$1.06B.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$1.19B 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$1.22B 10-Q · filed 2026-05-14 |
| 2025-12-31 | -$1.13B 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$1.06B 10-Q · filed 2025-11-06 |
| 2025-06-30 | -$996.94M 10-Q · filed 2025-08-07 |
| 2025-03-31 | -$926.07M 10-Q · filed 2025-05-12 |
| 2024-12-31 | -$932.15M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$880.96M 10-Q · filed 2024-11-06 |
| 2024-06-30 | -$821.37M 10-Q · filed 2024-08-01 |
| 2024-03-31 | -$768.38M 10-Q · filed 2024-05-08 |
| 2023-12-31 | -$705.05M 10-K · filed 2025-03-13 |
| 2023-09-30 | -$642.16M 10-Q · filed 2023-11-08 |
| 2023-06-30 | -$580.29M 10-Q · filed 2023-08-02 |
| 2023-03-31 | -$508.23M 10-Q · filed 2023-05-03 |
| 2022-12-31 | -$441.55M 10-K · filed 2024-02-27 |
| 2022-09-30 | -$381.62M 10-Q · filed 2022-11-03 |
| 2022-06-30 | -$306.13M 10-Q · filed 2022-08-03 |
| 2022-03-31 | -$237.96M 10-Q · filed 2022-05-04 |
| 2021-12-31 | -$161.23M 10-K · filed 2023-02-28 |
| 2021-09-30 | -$455.25M 10-Q · filed 2021-11-02 |
| 2021-06-30 | -$396.85M 10-Q · filed 2021-08-09 |
| 2021-03-31 | -$339.21M 10-Q · filed 2021-05-05 |
| 2020-12-31 | -$289.07M 10-K · filed 2022-03-01 |
| 2020-09-30 | -$242.83M 10-Q · filed 2020-11-04 |
| 2020-06-30 | -$251.62M 10-Q · filed 2020-08-06 |
| 2020-03-31 | -$217.86M 10-Q · filed 2020-05-07 |
| 2019-12-31 | -$177.82M 10-K · filed 2021-03-01 |
| 2019-09-30 | -$151.36M 10-Q · filed 2019-11-05 |
| 2019-06-30 | -$116.77M 10-Q · filed 2019-08-07 |
| 2019-03-31 | -$115.32M 10-Q · filed 2019-05-07 |
| 2018-12-31 | -$83.02M 10-K · filed 2020-02-26 |
| 2018-09-30 | -$87.32M 10-Q · filed 2018-11-07 |
| 2018-06-30 | -$68.12M 10-Q · filed 2018-08-08 |
| 2018-03-31 | -$78.71M 10-Q · filed 2018-05-08 |
| 2017-12-31 | -$187.76M 10-K · filed 2019-02-27 |
| 2017-09-30 | -$171.76M 10-Q · filed 2017-11-08 |
| 2017-06-30 | -$151.05M 10-Q · filed 2017-08-08 |
| 2017-03-31 | -$136.58M 10-Q · filed 2017-05-09 |
| 2016-12-31 | -$114.59M 10-K · filed 2018-03-06 |
| 2016-09-30 | -$94.98M 10-Q · filed 2016-11-09 |
| 2016-06-30 | -$76.83M 10-Q · filed 2016-08-09 |
| 2016-03-31 | -$62.39M 10-Q · filed 2016-05-05 |
| 2015-12-31 | -$51.62M 10-K · filed 2017-03-07 |
| 2015-09-30 | -$46.44M 10-Q · filed 2015-11-05 |
| 2014-12-31 | -$28.81M 10-K · filed 2016-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |